A Blueprint for Changing Diabetes in Indonesia
Novo Nordisk’s latest Blueprint for Change case shows how barriers to diabetes care in Indonesia can be broken down to improve the lives of millions.
4 April 2013 /3BL Media/ - Among the 242 million people living in Indonesia, 7.6 million have diabetes but less than one per cent is achieving recommended treatment targets. In its fifth Blueprint for Change business case published today, Novo Nordisk examines four barriers that prevent quality and accessibility of diabetes care and identifies the opportunities to address them.
“If action is not taken, demand for healthcare will outstrip Indonesia’s ability to provide it,” says Charlotte Ersbøll, corporate vice president, Global Stakeholder Engagement, Novo Nordisk. “In the end, it will be people with diabetes and their families that will carry the highest cost.”
The Indonesia Blueprint for Change recommends investments in diabetes awareness, increasing the supply of healthcare professionals specialising in diabetes care and improving diabetes education among internists and general practitioners. Concrete action suggested is the need to involve more levels of healthcare professionals, including nurses and diabetes educators. A final conclusion from the case is the need to make these investments in partnerships.
“Novo Nordisk is committed to working together with local authorities, investors and NGOs to build trust and confidence among patients, healthcare practitioners and policy makers,” says Sandeep Sur, general manager, Novo Nordisk Indonesia. “We must leverage all our joint capabilities and competences if we want to improve knowledge, treatment and better care.”
According to the analysis, improved awareness, accessibility, affordability and quality of care could reduce both diabetes-related complications and costs. Over the remaining lifetime of people with diabetes in Indonesia, more than 37,000 diabetes-related heart attacks and more than 400,000 diabetes-related kidney failures could be prevented, nearly 6 billion USD could be saved in diabetes treatment costs and more than 4.6 million life-years could be gained.
Learn more
Explore the four previous Blueprint for Change business cases
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. In 2013, Novo Nordisk received the Pharmaceuticals and Biotechnology industry group top ranking on Corporate Knight’s list of Global 100 Most Sustainable Corporations. For more information, visit novonordisk.com/sustainability.
